Blood Cancer Journal


Publication Venue For

  • Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy.  12. 2022
  • Clinical and therapeutic implications of BRAF fusions in histiocytic disorders.  12. 2022
  • Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis.  12. 2022
  • Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.  11. 2021
  • High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group.  11. 2021
  • Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.  11. 2021
  • Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study.  10. 2020
  • The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm.  10. 2020
  • Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.  9. 2019
  • Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: Are we using realistic estimates?.  8. 2018
  • Clinical and radiological responses to oral methotrexate alone or in combination with other agents in erdheim-chester disease.  7. 2017
  • Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: Analysis using a national data set.  7. 2017
  • Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.  7. 2017
  • Prevalence, incidence and survival of smoldering multiple myeloma in the United States.  6. 2016
  • Ibrutinib has some activity in Richter's syndrome.  5:e277. 2015
  • Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT..  4:e178. 2014
  • Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: Role of drug metabolism, apoptosis and DNA repair.  2. 2012
  • International Standard Serial Number (issn)

  • 2044-5385
  • Electronic International Standard Serial Number (eissn)

  • 2044-5385